In the second episode of our mini-series "Conversations about Hypertrophic Cardiomyopathy", Dr Ankur Kalra sat down with Dr Ahmad Masri to have a deep-dive into the management paradigms of hypertrophic cardiomyopathy (HCM), considering the evolution of medical therapy in recent years. Dr Ahmad Masri is a Cardiologist and the Director of OHSU Hypertrophic Cardiomyopathy Center.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
Dr Kalra invites Dr Masri to guide us through his decision-making process in evaluating medical and surgical options in patients with obstructive hypertrophic cardiomyopathy. Dr Masri delves into first and second-line treatment strategies while exploring the significance of FDA-approved cardiac myosin inhibitors in the management of hypertrophic cardiomyopathy. Dr Kalra asks Dr Masri about the practical office-based clinical course for patients deemed suitable candidates to receive mavacamten. Dr Masri provides a clear and practical outline of what it entails to opt for this second-line medical therapy including the REMS programme required for therapy (www.camzyosrems.com). Dr Masri highlights the importance of looking at HCM patients holistically to find the treatment which best fits their circumstances and preferences in choosing surgical and medical therapy options.
What are the available management options for patients with HCM? How does Dr Masri approach shared decision-making in the management of HCM? What are some of the practical considerations regarding the cardiac myosin inhibitor, mavacamten?
This content is intended for US-based physicians.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb.
Dr Owens is Medical Director of the Center for Inherited Cardiac Disease and Associate Professor of Medicine at the Hospital of the University of Pennsylvania.
This series is supported by an unrestricted educational grant from Bristol Myers Squibb. Please see www.camzyosrems.com for important safety information.
This content is intended for US-based physicians.
What is the Global Cardiology University project? How does Dr Anavekar encourage trainees to re-examine their role in patient care? What is his advice to our listeners?
As Dr Kalra asks Dr Rao about the ways in which early career faculty members can get involved with the organization at a state level. Dr Rao shares his insider tips and highlights key events where individuals can further their participation.
How can you get involved with your local ACC chapter? How can you improve your leadership skills? What is Dr Rao’s advice for our listeners?
He explains how the complexity of nutrition and the compounds generated by the gut microbiome can impact our health. We learn more about three compounds produced by our gut microbiome that have a strong connection with heart disease.
Through this conversation, Dr Vuyisich invites us to reframe our approach to nutrition and prevention as a question of food education and data-driven science.
This episode features a vascular neurologist and an interventional cardiologist who will discuss the relationship between their two fields of medicine.
In this rich and insightful discussion, Dr Kittleson talks about the origins of famous #kittlesonrules, a collection of tips for doctors shared on Twitter, and her thoughts on mentorship. We learn more about Mastering the Art of Patient Care. Dr Kalra and Dr Kittleson discuss strategies for managing difficult situations in patient care.
What do you need to know about hospital investigations? What is the difference between OPPE and FPPE? How can you get educated on hospital bylaws and processes?
